Preclinical Development of Selective YTHDF2 Binders for AML Treatment

• Unité de recherche: INNOSUISSE
• Numéro de projet: 133.757 IP-LS
• Titre du projet anglais: Preclinical Development of Selective YTHDF2 Binders for AML Treatment

Mots-clé (Anglais)

Life sciences, Pharmaceuticals

Résumé des résultats (Abstract) (Anglais)

The main goal is to found a spin-off as a platform for developing selective binders targeting YTHDF2, a key RNA-binding protein involved in acute myeloid leukemia. We aim to leverage our generative AI technology for developing a strong preclinical candidate and bring it toward commercialization.